Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JPMorgan ups Amazon target, says buy on the weakness
JPMorgan analyst Doug Anmuth admits that after four quarters of "big beats and clean results," Amazon.com's Q4 results last night were more mixed. The analyst, however, believes Amazon's "strong topline growth trajectory" in unchanged. He expects the company's margin expansion to continue. Anmuth raised his price target for the shares to $825 from $800 and reiterates an Overweight rating on the name. He recommends buying Amazon on today's selloff. The stock is down $62.35 to $573.00 in pre-market trading.
no, base you're arguments on something other than pure spew - you're just taking up space doing that
you're treading a very fine line. all good discussion welcome but your posts do not contribute by calling WS scammers!
it ran up over 20% in a few weeks, something wrong in taking profit? I see a short downtrend going forward but of course could be wrong. Not really pertinent for name calling
Jumping off for a short time, think it'll drift back down - taking nice profit. Back in at 2 if it comes
AMZN is my strong BUY since yesterday
been done many a time before. Yes, any insider need to inform the SEC:
http://www.sec.gov/answer/insider.htm
Insider Reports Filed with the SEC
Forms 3, 4, 5
These forms are used for insider trades; learn how to access them through the SEC's EDGAR database.
http://www.sec.gov/answers/form345.htm
AMZN Stock: If Amazon.com, Inc. Pulls This Off, Shares Could Skyrocket
4
Amazon StockAmazon.com Shareholders Need to Watch This
Amazon.com, Inc. (NASDAQ:AMZN) was, hands down, the biggest growth story of 2015. But can the run continue into 2016? That’s the question bothering the loyal investors who witnessed a steady drop in AMZN stock since the beginning of this year. My one-word answer will hopefully solace them:
Yes!
Well, it’s likely to continue anyway. There are no sure things in the stock market, but bear with me as I explain how.
A ship doesn’t steer itself. It is the captain who does; for even the unsinkable ships can sink under an incapable captain. The same metaphor is true for the business world.
Amazon owes its “amazonic” success to none other than its founder and captain, Jeff Bezos, whose unique business mantra sets him apart from most average CEOs—which is, to stay forever young!
The man takes lessons from history and knows what it takes to stay relevant in the business world. Putting it in his words, “All businesses need to be young forever. If your customer base ages with you, you’re Woolworth’s.” (Source: “Bezos courts Washington Post editors, reporters,” Washington Post, September 4, 2013.)
From print media to space exploration, the man has privately gotten his hands dirty in about every business one could think of. Bezos’ daring persona to try anything and everything to stay young is what has kept Amazon ahead of the game.
To put this into perspective, take the example of Amazon’s “Fire Phone.” The idea behind launching its own smartphone was to create an Amazon-only ecosystem of services for mobile users. That idea bombed! But Bezos didn’t lose heart. He got a way around it.
Rumor has it that he is now out looking for partnerships with “Android” phone-makers to make Amazon’s software and services base an inherent part of the operating system (OS). In other words, Amazon will expand its ecosystem one way or another. There’s no stopping Bezos!
All eyes are now set on Amazon’s fourth-quarter results for 2015 that are due to be reported after the bell today. Bear in mind that Amazon has managed to surprise us throughout the last three quarters. I’m seeing this quarter to be no different.
Recall that the company had a stellar holiday sales season, reporting the biggest ever sell-through of Amazon devices. On the side, “Amazon Prime” membership also broke all prior records. So, its retail business is in spectacular shape. (Source: “Amazon devices double in sales as Prime members set new holiday records,” The Verge, December 28, 2016.)
Moving to its software business, “Amazon Web Services” (AWS) is also maintaining its northward momentum. This segment posted double-digit growth in excess of 78% in the last quarter alone and is a high-margin business segment, which means that this is what is lending significantly to Amazon’s recently-turned-green bottom line.
In fact, some analysts believe that the AWS segment could grow big enough to outpace Amazon’s core retail business segment by next year. (Source: “Amazon cloud service key to sustaining profitability,” Financial Times, January 26, 2016.) So we wouldn’t be wrong to expect similar stellar growth numbers from this segment, too.
The consensus earnings-per-share (EPS) estimate is $1.58 this quarter. That shouldn’t be too difficult to beat for Amazon on the back of all of these positive indicators. (Source: “Analyst Estimates,” Yahoo! Finance, last accessed January 27, 2016.)
The Bottom Line on AMZN Stock
For an average Joe, Amazon is an online shopping web site for good bargains on affordable merchandise. But Amazon has a come long way since its inception in the 90s. Today, it’s a full-blown technology and Internet services company, with a product offering as wide as e-commerce to technology hardware and enterprise software solutions.
With a product offering so wide and a market penetration so deep, only a fool would fail to acknowledge Amazon’s growing universal appeal. Plus, Amazon is headed by a daredevil CEO who is not afraid to take calculated risks in order to keep this company young and growing forever.
So long as the company continues to expand its ecosystem of products and services, holders of AMZN stock will continue to reap the rewards.
ALL FUTURES ARE UP SO NOT SURE WHERE YOU SEE MARKET GOING DOWN JUST YET
you must be short I take it. nonsensical post without any reason for your comment. Let's see after market who's right - my money is on up over $50!
I believe this guy is right:
Piper Jaffray Reiterates Buy Rating for Amazon.com, Inc. (AMZN)
January 25th, 2016 - By Micah Smith - 0 comments
Amazon.com logoAmazon.com, Inc. (NASDAQ:AMZN)‘s stock had its “buy” rating reissued by research analysts at Piper Jaffray in a research note issued to investors on Thursday, Market Beat reports. They presently have a $800.00 price target on the e-commerce giant’s stock. Piper Jaffray’s price target points to a potential upside of 34.11% from the stock’s previous close.
Several large investors recently added to or reduced their stakes in the stock. Creative Planning raised its stake in Amazon.com by 31.9% in the fourth quarter. Creative Planning now owns 49,597 shares of the e-commerce giant’s stock worth $33,522,000 after buying an additional 11,988 shares during the period. Marcus Capital bought a new stake in Amazon.com during the fourth quarter worth approximately $4,230,000. Meristem bought a new stake in Amazon.com during the fourth quarter worth approximately $890,000. ING Groep raised its stake in Amazon.com by 130.5% in the third quarter. ING Groep now owns 37,666 shares of the e-commerce giant’s stock worth $19,274,000 after buying an additional 21,325 shares during the period. Finally, Northcoast Asset Management bought a new stake in Amazon.com during the third quarter worth approximately $1,572,000.
Several other equities research analysts have also weighed in on the company. Vetr upgraded Amazon.com from a “sell” rating to a “hold” rating and set a $653.68 target price for the company in a report on Monday, November 16th. Credit Suisse upped their price target on Amazon.com from $570.18 to $800.00 and gave the stock an “outperform” rating in a report on Tuesday, January 19th. Monness Crespi & Hardt lowered Amazon.com from a “buy” rating to a “neutral” rating and upped their price target for the stock from $656.00 to $675.89 in a report on Monday, January 4th. They noted that the move was a valuation call. Zacks Investment Research upgraded Amazon.com from a “hold” rating to a “buy” rating and set a $738.00 price target for the company in a report on Wednesday, December 16th. Finally, Deutsche Bank reiterated a “buy” rating on shares of Amazon.com in a report on Sunday, October 4th. Nine equities research analysts have rated the stock with a hold rating, thirty-nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Amazon.com presently has an average rating of “Buy” and an average target price of $706.00.
Shares of Amazon.com (NASDAQ:AMZN) traded up 0.03% during trading on Thursday, hitting $596.53. 4,391,012 shares of the stock traded hands. Amazon.com has a 52 week low of $299.33 and a 52 week high of $696.44. The firm’s 50-day moving average price is $639.97 and its 200-day moving average price is $574.18. The company has a market cap of $279.63 billion and a price-to-earnings ratio of 854.63.
Amazon.com (NASDAQ:AMZN) last posted its earnings results on Thursday, October 22nd. The e-commerce giant reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.30. The company earned $25.36 billion during the quarter, compared to analyst estimates of $24.91 billion. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.95) earnings per share. On average, equities research analysts anticipate that Amazon.com will post $1.87 earnings per share for the current year.
In other Amazon.com news, Director Patricia Q. Stonesifer sold 6,250 shares of the company’s stock in a transaction dated Thursday, December 3rd. The stock was sold at an average price of $678.86, for a total value of $4,242,875.00. Following the sale, the director now owns 25,423 shares in the company, valued at approximately $17,258,657.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas O. Ryder sold 4,000 shares of the company’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $636.84, for a total value of $2,547,360.00. Following the completion of the sale, the director now owns 24,653 shares in the company, valued at approximately $15,700,016.52. The disclosure for this sale can be found here.
Amazon.com, Inc. (NASDAQ:AMZN) is an e-commerce company. The Company sells a range of products and services through its Websites. The Company’s products are offered through consumer-facing Websites, which include merchandise and content that it purchases for resale from vendors and those offered by third-party sellers. It designs its Websites to enable products to be sold by the Company and by third parties across various product categories. It also manufactures and sells electronic devices, including Kindle e-readers, Fire tablets, Fire TVs, Echo and Fire phones. Amazon.com operates in two segments: North America and International. The North America segment focuses on retail sales earned through North America-focused Websites. The International segment focuses on the Company’s operations done through its international Websites. It serves developers and enterprises through Amazon Web Services (AWS). It serves authors and independent publishers with Kindle Direct Publishing.
The sector is going gangbusters other than apple who has stopped innovating. Look at the AWE business alone. I think we could see new high Friday
VPOR does not have $450k in my opinion. They have not announced any stock buy-back (but technically could be buying their own stock). I believe OS is closer to 9 billion shares, i also believe debt has increased and nothing paid down, just my opinion. Also, in your scenario you assume the stock price would go up from $0.0001 pre-split or $0.001 after split just because 4.5b shares traded pre-split (does not matter who bought them) to $0.10 pre-split or $1.00 post split - 1000 times. You're dreaming. If the stock trades at $0.0001 it's not worth more.
Why Amazon.com, Inc. (AMZN) Stock Will Rip Another 15% Higher
Investors getting the jitters ahead of Amazon's upcoming earnings report can breathe easy
By Johnson Research Group | Jan 26, 2016, 10:45 am EST
RSS Logo Johnson Research Group
Amazon.com, Inc. (AMZN) heads into its earnings report this Thursday with Wall Street analysts expecting that Amazon stock is ready to start going the way of Apple Inc. (AAPL).
Amazon Has Some Online Competition 300x168 Why Amazon.com, Inc. (AMZN) Stock Will Rip Another 15% Higher
Source: Grab Media
They couldn’t be more wrong.
While many still think of AMZN as the retail giant that it is, there are so many facets to the company that are shining brighter than the retail business — facets that are setting Amazon stock up for the next decade of performance, not the next year.
Amazon Web Services
We’ll start with the Amazon Web Services, a business line that many investors may not even be aware of. The web services arm of Amazon represents a cloud computing initiative that operates in 12 different regions of the world.
I know, cloud computing is nothing new to the market, but Amazon’s dominance isn’t as well-known as it should be.
For instance, last year, revenue for Amazon Web services was more than the cumulative revenue for their four largest competitors. Who is the competition in the space? How about Microsoft Corporation (MSFT), Alphabet Inc (GOOG, GOOGL), International Business Machines Corp. (IBM) and Salesforce.com, Inc. (CRM). Last quarter’s revenue for AWS showed growth of 78% on a year-over-year basis, blowing the doors off their competitors.
4 Vanguard Funds I’ll Never Sell
Buying these Vanguard funds was one of the most profitable decisions of my investing life. And they can change your life, too! You’ll find their names and complete details in my latest Special Report. It’s yours FREE when you click here.
This will be the No. 1 data point that we will be watching on the earnings release on Thursday after the close as a continuation in the breakneck revenue growth is likely to drive Amazon stock into the stratosphere.
Logistics
Moving on, Amazon continues to build out some of its future as the company is moving toward claiming its own logistics network. Recently, Re/code reported that the company had obtained a license to ship freight from China — just one of many moves that investors should be taking note of.
AMZN appears to be expanding its logistics reach to the point where it seems to be building channels all the way from producers to consumers. In addition to overseas shipping and plans to complete an acquisition of French delivery company Colis Privé, Amazon has been rumored to be interested in potential regional air hubs and acquiring leases on 20 airplanes.
If you’re United Parcel Service, Inc. (UPS) you have to start getting concerned about Amazon running its own packages to customers’ doorsteps — or even worse, someday delivering other companies’ packages through an efficient logistics network.
A Look at Amazon Stock
012616 amzn preview Why Amazon.com, Inc. (AMZN) Stock Will Rip Another 15% Higher
Unlike the vast majority of stocks in the S&P 500, Amazon stock remains technically sound as the shares are trading above their 200-day moving average and the longer-term 20-month moving average. That technical strength will continue to attract traders and investors alike.
If there’s a hitch in the short-term outlook for AMZN, it’s the sentiment heading into this week’s earnings announcement. The current whisper number for Amazon earnings is $1.70 per share compared to Wall Street analyst’s expectations of $1.61.
The 5.6% higher whisper number suggests there could be some selling pressure on the shares even if the company matches Wall Street’s expectations, though we would consider any short-term selling as an opportunity to grab this relative strength performer “on sale.”
In addition to the whisper estimates showing optimism in AMZN, the current short interest and analyst recommendations suggest there is somewhat of a crowded trade forming on Amazon stock. While we usually avoid stocks with these signs, it is important to remember one of the most important rules of contrarian research, which is that sentiment is most powerful when it is counterintuitive to the stock’s fundamental and technical outlooks.
In other words, the strength of trend and fundamentals will override the relatively optimistic sentiment.
With this in mind, we’re expecting Amazon stock to fall within an acceptable win/loss scenario. On the win side, we see a target of $695 — a 15% move from Monday’s close. Downside risk is a move to the stock’s 200-day moving average, currently at $529, or about 10% from Monday’s close. From this perspective, we’re risking 10% to gain 15% … and if AMZN did move to the low range, we would dollar-cost average into existing positions to lower our cost per share, which would only raise the net return when the stock eventually hits our upside target.
Bottom line, Amazon stock deserves an allocation in most investors’ portfolios during 2016. Grab it before it runs higher.
As of this writing, Johnson Research Group did not hold a position in any of the aforementioned securities.
your math is flawed. If they split 1 for 10 and assuming 5 billion shares outstanding (I believe it to be much higher) then there would be 500M shares outstanding. If the price was $0.0001 before the split the price after the split would be $0.001
Reverse Stock Splits
A reverse stock split reduces the number of shares and increases the share price proportionately. For example, if you own 10,000 shares of a company and it declares a one for ten reverse split, you will own a total of 1,000 shares after the split. A reverse stock split has no effect on the value of what shareholders own. Companies often split their stock when they believe the price of their stock is too low to attract investors to buy their stock. Some reverse stock splits cause small shareholders to be "cashed out" so that they no longer own the company’s shares.
A company’s board of directors may declare a reverse stock split without shareholder approval. Although the SEC has authority over a broad range of corporate activity, state corporate law and a company’s articles of incorporation and by-laws govern reverse stock splits.
If a company is required to file reports with the SEC, it may notify its shareholders of a reverse stock split on Forms 8-K, 10-Q and 10-K.
https://www.sec.gov/answers/reversesplit.htm
2'S ARE THERE NOW
Big tobacco would not touch VPOR with a 1,000 foot pole. VPOR would not pass the DD by a 10 year old!
one could also look from the other side and be devils advocate:
1. Nothing good to PR - if Hoverboard sales were off the hinges they surely would have PR'd it
2. that reputable firm might have run across some very serious issues
3. how good are they at marketing their products? Stores closed on the Vapor side, Distributors not re-ordering (at least products gone missing from catalogs). Hoverboard - no verification that the BATTERY is UL certified (only the power supply). Not back on Amazon
4. Revenues are a total blank due to lack of reporting
5. CBD products pulled and also a lot of competition
On top of that the background on Dror and his prior endeavors in public companies is not a rosy picture. Big unknown is also the SEC and their potential involvement.
At this stage it is a guessing game and the risk is then obviously extreme.
$800 target:
Piper Jaffray analyst, Gene Munster, thinks street estimates are too low for Amazon.com (NASDAQ: AMZN) and there could be upside in the coming year. In short, he believes Amazon can invest in the business while expanding margins which is not in consensus estimates. His thesis has 3 points:
Concerns over margin compression returning from AWS & fulfillment expansion are misunderstood. Munster believes that Amazon does not pendulate on profitability as perceived. While many believe 2015 margin expansion was due to Amazon cutting back expansion plans and R&D experiments, it is due to Amazon's $10B of gross profit growth, its first year of fulfillment leverage, and massive Prime adoption.
Street estimates are mis-modeling margin expansion in 2016. Munster is modeling 240bps of operating margin expansion in 2016, largely from leveraging fixed assets. The company will expand margins through lower retargeting expense for new Prime members, AWS's growing share of revenue, expansion of robotics, mix shift towards 3P sales, leveraging India infrastructure, and higher margin revenue sources.
Unit growth should exceed expectations. The Amazon Search Index indicates that unit growth during the quarter was likely in the 24%-26% range, consistent with his analysis of Amazon's full year operating disclosures. His index has a .95 correlation with reported unit growth over the past 31 quarters. Despite strong unit growth YTD, he believes investors are expecting 22%-24% unit growth.
No change to Overweight rating or $800 PT.
For an analyst ratings summary and ratings history on Amazon.com click here. For more ratings news on Amazon.com click here.
Shares of Amazon.com closed at $596.38 yesterday.
Watch Amazon get past $700 on February 29th!
Even though the whole market is up nicely this stock is not trading with the market but showing nice legs nonetheless. Still needs more volume but I think that will be coming.
https://www.facebook.com/StocksandMoney/ has a strong buy with $10 target
Good luck!
lack of volume probably reflects that buyers are waiting for the variables to sort out and the longs believe it's not going lower. I believe this will be a 2017 story, up or down.
I think it has all the makings of a success story. I am long indeed, actually doubled up around $2
someone should update intro. I applied for mod status but no response
I have time, think it will move over next few months.
I saw that and view that as bullish also. Zacks had a target of $9 not too long ago. This could easily provide some good ROI
Cancer Genetics Inc (NASDAQ:CGIX) Given Average Rating of “Strong Buy” by Brokerages
Posted by Wayne Rhoads on Jan 18th, 2016 // No Comments
Cancer Genetics logoShares of Cancer Genetics Inc (NASDAQ:CGIX) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price objective of $7.00 for the company and are predicting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also assigned Cancer Genetics an industry rank of 15 out of 265 based on the ratings given to its competitors.
A number of equities analysts have weighed in on CGIX shares. Aegis reissued a “positive” rating on shares of Cancer Genetics in a research report on Tuesday, October 6th. Zacks Investment Research upgraded Cancer Genetics from a “hold” rating to a “strong-buy” rating and set a $9.00 price objective for the company in a report on Tuesday, October 13th.
Shares of Cancer Genetics (NASDAQ:CGIX) opened at 2.24 on Wednesday. The company’s 50-day moving average price is $2.96 and its 200-day moving average price is $7.20. Cancer Genetics has a 12-month low of $1.90 and a 12-month high of $12.75. The firm’s market capitalization is $23.86 million.
Cancer Genetics (NASDAQ:CGIX) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by $0.07. During the same quarter in the previous year, the business posted ($0.51) earnings per share. The business earned $4 million during the quarter, compared to analysts’ expectations of $5.13 million. The firm’s revenue was up 25.0% on a year-over-year basis. Analysts anticipate that Cancer Genetics will post ($1.94) EPS for the current year.
Cancer Genetics Inc (CGIX) Stake Held by Sabby Healthcare Master Fund, Ltd
January 20th, 2016 - 0 comments - Filed Under - by John Ramos
Cancer Genetics logoSabby Healthcare Master Fund, Ltd disclosed that they own 5% of Cancer Genetics Inc (NASDAQ:CGIX) in a Schedule 13G/A disclosure that was filed with the SEC on Thursday, January 14th. The investor owns 531,531 shares of the stock valued at about $1,084,323. The reporting parties listed on the disclosure included Sabby Healthcare Master Fund, Ltd, Sabby Volatility Warrant Master Fund, Ltd, Sabby Management, LLC and Hal Mintz. The filing is available through the SEC website at this link.
Shares of Cancer Genetics Inc (NASDAQ:CGIX) opened at 2.04 on Wednesday. The company has a 50-day moving average of $2.89 and a 200-day moving average of $7.06. Cancer Genetics Inc has a 12-month low of $1.90 and a 12-month high of $12.75. The stock’s market capitalization is $21.73 million.
Cancer Genetics (NASDAQ:CGIX) last announced its earnings results on Tuesday, November 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.49) by $0.07. During the same period in the previous year, the company earned ($0.51) EPS. The company had revenue of $4 million for the quarter, compared to analysts’ expectations of $5.13 million. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year. Equities analysts expect that Cancer Genetics Inc will post ($1.94) earnings per share for the current fiscal year.
A number of equities research analysts have recently commented on CGIX shares. Zacks Investment Research upgraded shares of Cancer Genetics from a “hold” rating to a “strong-buy” rating and set a $9.00 price target for the company in a report on Tuesday, October 13th. Aegis reiterated a “positive” rating on shares of Cancer Genetics in a report on Tuesday, October 6th.
Cancer Genetics, Inc. is an oncology diagnostics company focused on developing, commercializing and providing DNA-based tests and services. The business is based on demand for DNA-based diagnostic services from three main sectors, including cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community. Its clinical offerings include its portfolio of proprietary tests targeting hematological, urogenital and HPV-associated cancers, in conjunction with ancillary non-proprietary tests. Biopharma services include laboratory and testing services performed for biopharmaceutical companies engaged in clinical trials. Discovery services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease.
Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, ...
Date : 01/21/2016 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Cancer Genetics, Inc. (MM) (CGIX)
Quote : 2.19 0.0 (0.00%) @ 7:49AM
Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, ...
Print
Alert
Cancer Genetics, Inc. (NASDAQ:CGIX)
Intraday Stock Chart
Today : Thursday 21 January 2016
Click Here for more Cancer Genetics, Inc. Charts.
Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics announced today that it has developed and launched a comprehensive portfolio of tests and technologies to help measure and monitor immuno-oncology markers and select patients for targeted therapies. This portfolio will be available for clinical trials, patient care, and translational research utilizing multiple technological platforms and will be available at CGI’s New Jersey and Los Angeles facilities. In addition, the newly acquired Center of Excellence For Solid Tumor Testing based in Los Angeles, formerly Response Genetics, will also offer the FDA-approved PDL-1 antibody for selection of patients that are most likely to benefit from key immuno-oncology drugs.
Immuno-oncology is a highly promising area of medicine and has already seen several blockbuster therapies enter the market in disease areas such as non-small cell lung cancer and melanoma. Several of these drugs require identification of patients that have a high likelihood of response. As a result, healthcare professionals require identification and potentially companion diagnostics to facilitate patient care. Clinical trials, targeted therapies that are under development, and many existing approved oncology drugs are undergoing clinical research to identify patient groups that can benefit from stimulating an effective immune response against cancer. The goal is to achieve a more durable or more effective response to the therapy.
Immuno-oncology drugs by themselves have been shown to be highly effective in 20 to 30 percent of patients, and combination therapies are bringing the promise of more significant patient benefits. In order to develop more effective treatments with fewer side effects, immune-oncology biomarkers and tests helping to assess the effects of therapies will play a key role.
Wall Street analysts are projecting over $35 billion in annual worldwide sales for immuno-oncology drugs by 2024, which would account for half of all spending on cancer drugs, according to market research firm IMS Health. According to pharmaceutical analysts, major pharmaceutical multinational companies are all expected to spend nearly $1 billion a year on immuno-oncology research, early access, and development programs and clinical trials. CGI offers the entire portfolio of immuno-oncology testing and technologies to help pharmaceutical and biotech companies accelerate their clinical trials by integrating immune response data with the genomic and biomarker data that CGI currently provides. This integrated offering will be critical in expanding the CGI value proposition to biotech and pharma companies and increasing the total addressable market for CGI.
“In an era of precision and increasingly personalized therapy, the healthcare industry demands cost-effective options that can robustly identify biomarkers to help select cancer patients most likely to benefit from the emerging class of immuno-oncology drugs,” said Panna Sharma, President and CEO. “CGI has prepared an extensive portfolio of technologies ranging from Immunohistochemistry (IHC) and immuno-phenotyping by flow cytometry to RNA-sequencing. These technologies address the tremendous demand we are experiencing by providing both genomic and immune-marker information to clinical trials and patient care.”
The CGI portfolio of immuno-oncology tests includes immunohistochemistry (IHC)-based tests that can detect novel biomarkers like PD-1 and PD-L1 and flow cytometry-based tests and panels that can assess immune response against cancers by evaluating subsets of immunomodulatory and effector cells. CGI also offers a next generation sequencing (NGS)-based targeted RNA sequencing test that can measure expression levels of drug targets, tumor infiltrate composition, and total immune cell composition. Many of these assays are also available for clinical use and are CLIA- and New York State-approved.
Several drugs targeting PD-1/PD-L1 interactions are currently either FDA approved or in clinical trials. Assessment of PD-L1 expression on tumor cells and in tumor microenvironments is currently used as a biomarker for immunotherapies in patients who fail first-line treatment for non-small cell lung cancer (NSCLC), melanoma, colon cancer, bladder cancer, and hematologic malignancies, among others.
CGI now offers commercial assays for anti-PD-L1 staining and assessment using IHC on formalin-fixed paraffin-embedded (FFPE) tissue for multiple tumor indications, including non-small cell lung cancer (NSCLC), colon adenocarcinoma, melanoma, and several subtypes of non-Hodgkin lymphoma. The in-house expertise of surgical and hemato-pathologists allows reliable evaluation of these markers using complex scoring schemes. Additionally, CGI has capabilities and reporting to integrate genomic and other biomarker data with the immune-marker status to provide a systems approach to measuring and monitoring patients.
CGI will continue expanding the overall capabilities in immuno-oncology and immunotherapy and integrate these capabilities with the genomic and biomarker-based testing being provided in both its New Jersey and Los Angeles centers of excellence.
About Cancer Genetics
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow CGI at:
Internet: http://www.cancergenetics.com?
Twitter: @Cancer_Genetics?
Facebook: www.facebook.com/CancerGenetics? ?
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended September 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Media Contact:
Cancer Genetics, Inc.?
Marie-Agnes Patrone-Michellod,PhD.?
Tel: 201.528.9200?
Email: marie.michellod@cgix.com
Looked into it and concluded this is a buying opportunity. Do your own due diligence
you are correct. VPOR is indeed registered with the SEC.
I found this interesting> http://www.auditanalytics.com/blog/accounting-related-nt-filings/
Pink sheets-listed companies have no requirement to be listed. All a company needs to do to get listed on the pink sheets is submit a form, entitled Form 211, with the OTC Compliance Unit. Usually this is done on behalf of a company by a market maker. The form must have current financial information. The more willing a company is to show its books, the easier it is for a broker-dealer to quote a price for that company. Some companies will make it easier and others will not - they are under no obligation to do so, and because of this, transparency is not comparable to financials for exchange-listed companies.
Pink sheets-listed companies are usually very small, tightly held and may also be thinly traded. The most difficult part about the pink sheets-listed companies is many of them do not even file annual or periodic reports with the Securities & Exchange Commission (SEC). This can make it very difficult - if not nearly impossible - for an average investor to get any real information regarding these companies. (To learn more, check out SEC Filings: Forms You Need To Know.)
Read more: The Over-The-Counter Market: An Introduction To Pink Sheets | Investopedia http://www.investopedia.com/articles/fundamental-analysis/08/pink-sheets-ottcb.asp#ixzz3x9LosY9t
Follow us: Investopedia on Facebook
Funny thing is that on the pinks there's really no requirement for financials at all. The only "action" OTC takes is put up a warning sign which currently is the yield sign:
Limited Information
Designed for companies with financial reporting problems, economic distress, or in bankruptcy to make the limited information they have publicly available. The Limited Information category also includes companies that may not be troubled, but are unwilling to provide disclosure pursuant to OTC Pink Basic Disclosure Guidelines.
Next step would be the Stop sign:
No Information
Indicates companies do not provide disclosure. Publicly traded companies that do not provide information to investors should be carefully researched before making any investment decision.
Final sign would be the Caveat Emptor symbol:
OTC Markets Group identifies securities with a Caveat Emptor symbol to inform investors that there may be reason to exercise additional care and perform thorough due diligence in making investment decisions for a particular security. The Caveat Emptor symbol is displayed in place of the OTCQX, OTCQB or OTC Pink marketplace designations and is distributed on market data feeds. The symbol is displayed wherever OTC Markets Group quote data is available. The designation is available to all market participants, including investors, broker-dealers, and clearing firms, so that they can make informed trading decisions.
I am not saying anything other than stating facts
UL certification and manufacturer
The UL certificate that is posted on Whizboard facebook page is for the switching adapter (which is a power supply), it is not for the battery pack. The cert is written to this company: http://www.nanguagu.com/p4_dongguan-aoi-electronic-technology-co-ltd-2746.html
The list the hoverboards on this page on Alibaba (note prices for better DD): http://dgaoi.en.alibaba.com/productgrouplist-802376411/Self_balancing_Electric_Scooter.html
Batteries are listed as: Battery: 158W/4.4AH(LG/samsung batteries.22P)
Your VPOR management:
https://www.facebook.com/dror.svorai
https://www.facebook.com/ynahon
Link works fine here
The Manufacturer VPOR uses: http://www.unicyclefreego.com/
Here's the Manufacturer offering these boards on Alibaba:
http://www.alibaba.com/product-detail/Proper-price-2-wheels-self-balancing_60322571763.html?spm=a2700.7724857.29.127.AmbxZe
interesting.....